Journals / Retina-Vitreus / 2012 / Cilt: 20 - Sayı: 2

The association between labile hemoglobin A1c and type II diabetic retinopathy

Labil hemoglobin A1c ve Tip II diyabetik retinopati arasındaki ilişki

Pages
124–128
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

It seems as an auxiliary parameter which is useful for follow-up of metabolic control of the patients in diabetic retinopathy.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: To investigate the association of labile hemoglobin A1c (LHbA1c) that is formed as a pre-product during synthesis of hemoglobin A1c (HbA1c) with diabetic retinopathy (DR) and HbA1c.
📊
Key Findings & Data:Materials and Methods: A total of 91 patients were enrolled in the study which included 32 patients with type II diabetes and DR (group 1), 30 patients with type II diabetes and without DR (group 2) and 29 patients without diabetes and DR (group 3).
💡
Conclusion & Impact:It seems as an auxiliary parameter which is useful for follow-up of metabolic control of the patients in diabetic retinopathy.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Purpose: To investigate the association of labile hemoglobin A1c (LHbA1c) that is formed as a pre-product during synthesis of hemoglobin A1c (HbA1c) with diabetic retinopathy (DR) and HbA1c. Materials and Methods: A total of 91 patients were enrolled in the study which included 32 patients with type II diabetes and DR (group 1), 30 patients with type II diabetes and without DR (group 2) and 29 patients without diabetes and DR (group 3). The patients with DR were subdivided into two groups; those with non-proliferative DR (group 1A:18 patients) and those with proliferative (group 1B:14 patients). Fasting blood glucose, HbA1c and LHbA1c were measured with biochemical analysis and compared statistically between the groups. Results: Mean HbA1c values were 8.9±1.4% (6.5-12.2) in group 1, 7.9±1.7% (5.3-11.9) in group 2 and 4.9±0.2% (4.3-5.2) group 3 (p<0.001). Mean LHbA1c values were 3.1±0.4% (2.1-3.9) in group 1, 2.8±0.5% (2.0-3.8) in group 2 and 1.8±0.1% (1.6-2.0) in group 3 (p<0.001). Mean HbA1c values were 8.2±1.0% (6.5-10.0) in group 1A and 9.5±1.1% (8.2-12.0) in grup1B (p=0.004). Mean LHbA1c values were 2.9±0.4% (2.1-3.4) group 1A and 3.3±0.4% (2.8-3.9) in group 1B (p=0.039). 93.7% of the patients with retinopathy and 63.3% of those without retinopathy had 7.0% and above HbA1c values. 62.5% of the patients with retinopathy and 40% of those without retinopathy had 3.0% and above LHbA1c values. There was a positive correlation between LHbA1c and HbA1c (r=0.87, p<0.001). Conclusion: LHbA1c is associated with diabetic retinopathy and severity of retinopathy likewise HbA1c and as important as HbA1c in control of blood glucose. It seems as an auxiliary parameter which is useful for follow-up of metabolic control of the patients in diabetic retinopathy.

Özet

Amaç: Hemoglobin A1c (HbA1c) sentezi esnasında bir ön ürün olan Labil hemoglobin A1c (LHbA1c) ile diabetik retinopati (DR) ve HbA1c arasındaki ilişkiyi araştırmak Gereç ve Yöntem: Çalışmaya, tip II diyabeti ve DR’si olan 32 hasta (grup 1), tip II diyabeti olan ve DR’si olmayan 30 hasta (grup 2) ve diyabeti olmayan 29 hasta (grup 3, kontrol grubu) olmak üzere, toplam 91 hasta dahil edildi. DR’si mevcut olan hastalar, proliferatif olmayan DR (grup 1A: 18 hasta) ve proliferatif DR (grup 1B:14 hasta) olmak üzere iki alt gruba ayrıldı. Hastaların açlık kan şekeri, HbA1c ve LHbA1c değerleri biyokimyasal analiz yöntemleriyle ölçüldü ve gruplar arasında istatistiksel olarak karşılaştırıldı. Bulgular: Ortalama HbA1c değerleri, grup 1’de %8.9±1.4 (6.5-12.2), grup 2’de %7.9±1.7 (5.3-11.9) ve grup 3’de %4.9±0.2 (4.3-5.2) idi (p<0.001). Ortalama LHbA1c değerleri, grup 1’de %3.1±0.4 (2.1-3.9), grup 2’de %2.8±0.5 (2.0-3.8) ve grup 3’de %1.8±0.1(1.6-2.0) idi (p<0.001). Ortalama HbA1c değerleri, grup 1A’da 8.2±1.0 (6.5-10.0) ve grup1B’de 9.5±1.1 (8.2-12.0) tespit edildi (p=0.004). Ortalama LHbA1c değerleri, grup 1A’da 2.9±0.4 (2.1-3.4) ve grup 1B’de 3.3±0.4 (2.8-3.9) tespit edildi (p=0.039). HbA1c değerleri, retinopatisi olan hastaların %93.7’sinde, olmayan hastaların %63.3’ünde %7.0 ve üzerinde idi. LHbA1c değerleri, retinopatisi olan hastaların %62.5’inde ve olmayan hastaların %40’ında %3.0 ve üzerinde idi. LHbA1c ve HbA1c arasında pozitif bir korelasyon tespit edildi (r=0.87, p<0.001). Sonuç: LHbA1c, HbA1c gibi diyabetik retinopati ve retinopati şiddetiyle ilişkilidir ve kan şekeri kontrolünde, HbA1c kadar önemlidir. Diabetik retinopatide, hastaların metabolik kontrolünü takibi için kullanılabilir bir yardımcı parametre olarak görünmektedir.

🔖

Cite This Article

GÖKTAŞ, A., KARAKÜKCÜ, Ç., ATAŞ, M., DEMİRCAN, S. (2012). The association between labile hemoglobin A1c and type II diabetic retinopathy. Retina-Vitreus, Cilt: 20 - Sayı: 2, 124–128. https://ajindex.com/articles/308066

References (15)

  1. Pinhas-Hamiel O, Zeitler P. Acute and chronic complications of type 2 diabetes mellitus in children and adolescents. Lancet 2007;369:1823-31
  2. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-53
  3. Rani PK, Raman R, Chandrakantan A, et al. Risk factors for diabetic retinopathy in self-reported rural population with diabetes. J Postgrad Med 2009;55:92-96
  4. Rodriguez-Fontal M, Kerrison JB, Alfaro DV, et al. Metabolic control and diabetic retinopathy. Curr Diabetes Rev 2009;5:3-7
  5. Fong DS, Aiello L, Gardner TW, et al. Retinopathy in diabetes. Diabetes Care 2004;27:84-7
  6. Akaydın KC, Bilgin AB. Diyabetik retinopatide erken tanı ve medikal tedavi. Ret-Vit 2010;18:61-5
  7. Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86
  8. Bunn HF. Evaluation of glycosylated hemoglobin diyabetic patients. Diabetes 1981;30:613-7
  9. Singh R, Barden A, Mori T, et al. Advanced Glycation End- Products: A Review. Diyabetologia 2001;44:129-46
  10. The Diabetes Control and Complications Trial Research Group: The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes 1995;44:968-83
  11. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12
  12. Yağcı R, Erdurmuş M, Demir N, Ove ark. Tip 2 diyabetin retinal vasküler komplikasyonları ile serum akut faz reaktanları ve lipid düzeyleri arasındaki ilişki.T Oft Gaz 2008;38:230-5
  13. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998;352:837-53
  14. American Diabetes association standarts of medical care in diabetics. Diabetes Care 2004;27:15-35
  15. Bunn HF. Evaluation of glycosylated hemoglobin in diabetic patients. Diabetes 1981;30:613-7.